Navigation Links
High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology
Date:2/23/2011

that of the 37 patients who underwent surgery, 12 patients achieved a pathologic complete response.  Additionally, three patients achieved a complete clinical endoscopic response and refused surgery.  Importantly, only one patient required a feeding tube and one patient used total parenteral nutrition. There were no grade 4 hematologic adverse events. Grade 3 hematologic adverse events included neutropenia (6%) and grade 3 non-hematologic toxicities included nausea (7%), esophagitis (7%), and fatigue (5%).

"This phase II study with OPAXIO demonstrated an encouragingly high rate of complete disappearance of cancer in patients that underwent potentially curative surgery following chemoradiotherapy.  Moreover, the therapy had a low incidence of the severe inflammation of the esophagus that frequently requires a feeding tube observed with the current standard regimens," said Jack Singer, M.D., Chief Medical Officer of CTI. "We believe that this study provides preliminary clinical support to our belief that paclitaxel poliglumex is a potent and tumor-selective radiosensitizer."

About OPAXIO™OPAXIO™ (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX™, is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard pac
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. GlaxoSmithKline Accelerates Review of Exelixis XL880
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
(Date:12/19/2014)... Dec. 18, 2014  RESMED INC. (NYSE: RMD ... of fiscal year 2015 results on Thursday, January 22, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... ALR ), a global leader in enabling individuals to ... rapid diagnostics and health management, has declared a dividend of $3.00 ... ALR PR B).  The dividend will be paid ... equal to the quotient of (a) $3.00 divided by (b) 97% ...
... CVS Caremark Corporation (NYSE: CVS ) today ... will be making a presentation to investors at the ... 25, 2011. Mr. Merlo is scheduled to present at ... An audio webcast of the presentation will be broadcast ...
Cached Medicine Technology:
(Date:12/19/2014)... Slone Partners , a national ... information technology, and laboratory testing industries, has promoted ... Officer. The announcement comes after a year of ... presence in Boston and several new additions to ... the client experience," said Adam Slone, Chief Executive ...
(Date:12/19/2014)... in good shape seems to reduce your risk of high ... more than 57,000 Americans, including more than 35,000 with high ... Those in the poorest shape had a more than ... start of the study, compared to a 50 percent chance ... more than 8,000 people diagnosed with high blood pressure during ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... Unidesk Corporation today announced that the ... its inaugural class in August 2013, has successfully ... bring your own device (BYOD) and deliver a ... solution, comprised of Citrix XenDesktop and ... storage infrastructure and Unidesk virtual desktop ...
(Date:12/17/2014)... 17, 2014 No matter how far ... to eradicate the head louse parasite—a common childhood malady ... Each year between six and twelve million individuals will ... lice removal treatment company comes to the rescue, providing ... friendly. With its track record of customer service, and ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... A court in Fiji has awarded $458,755 in compensation to ... being administered// excessive oxygen in an incubator post-birth. ,Jashnil ... a hospital in Lautoka, northwestern Fiji, was kept in an ... Fiji Times newspaper. ,Kamni Devi, the boy's mother, ...
... report in the journal Chest, that obese patients should ... surgery//, and that their lack of physical fitness could ... ,It has been reported that the weight-loss ... an increasingly popular treatment among people who are morbidly ...
... A new study shows that the consumption of just one ... a milkshake could quickly prevent// the ‘good cholesterol’, HDL, from ... had also explained that not only does the ability of ... main reason for vascular disease, it can also impair the ...
... Reducing the size of abdominal fat cells – which are ... more than cutting calories// , according to new research from ... five-year study show that exercise should be added to the ... Ph.D., instructor in geriatric medicine at Wake Forest Baptist and ...
... Washington University School of Medicine in St. Louis have ... brain injury// as they do not penetrate deep into ... chemical reactions, potentially slowing the reactions that cause permanent ... ,Scientists used rats to validate a ...
... at Washington University School of Medicine in St. Louis have ... high blood pressure get less energy because of their reduced ... recent issue of the Journal of Nuclear Cardiology. ,"The ... the body," says Lisa de las Fuentes, M.D. ,Earlier ...
Cached Medicine News:Health News:Fiji Boy Compensated for Losing Eye-sight due to Medical Lapse 2Health News:Poor Fitness Might Increase The Risks After Obesity Surgery 2Health News:Study Shows That The Quality Of HDL Produced Depends On The Food Consumed 2Health News:Exercise Important in Reducing Size of Abdominal Fat Cells 2Health News:Current Cooling Devices Ineffective in Preventing Brain Injury 2Health News:Current Cooling Devices Ineffective in Preventing Brain Injury 3Health News:Current Cooling Devices Ineffective in Preventing Brain Injury 4Health News:Fat Metabolism Of Heart Muscles Affected By High Blood Pressure 2Health News:Fat Metabolism Of Heart Muscles Affected By High Blood Pressure 3
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
... Level 1 enables hospitals ... patient monitors to a ... Our temperature monitoring disposale ... are superior in their ...
Medicine Products: